Setting 
My Cart

Ordered before 17:30, shipped today - Support: (012) 800 456 789

Track Your Order

Toggle Nav
Close
  • Menu
  • Setting

Sabutoclax

Catalog No.
A4199
pan-Bcl-2 inhibitor
Grouped product items
Size Price Stock Qty
5mg
Special Price $65.25 Regular Price $145.00
In stock
50mg
Special Price $303.75 Regular Price $675.00
In stock
For scientific research use only and should not be used for diagnostic or medical purposes.

Tel: +1-832-696-8203

Email: sales@apexbt.com

Worldwide Distributors

No Related Posts

Background

Sabutoclax is an inhibitor of pan-Bcl-2 family with IC50 values of 0.32, 0.31, 0.20 and 0.62 μM for Bcl-2, Bcl-xL, Mcl-1 and Bfl-1, respectively [1].

Sabutoclax is a derivative of apogossypolone. It showed a high binding affinity to Bcl-xL both in NMR binding assay and in ITC assay, with a Kd value of 0.11μM. Sabutoclax also showed better cell membrane permeability than other apogossypolone derivatives. In PC3 cells, sabutoclax inhibited cell growth with EC50 value of 0.13 μM. In human BP3 cell line, sabutoclax induced cell apoptosis with IC50 value of 0.049 μM. In mice bearing M2182 cancer xenografts, administration of sabutoclax significantly reduced the tumor size. At dose of 5 mg/kg, sabutoclax induced near complete tumor growth suppression [1].

References:
[1] Wei J, Stebbins J L, Kitada S, et al. BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. Journal of medicinal chemistry, 2010, 53(10): 4166-4176.

Product Citation

Chemical Properties

Physical AppearanceA solid
StorageStore at -20°C
M.Wt700.78
Cas No.1228108-65-3
FormulaC42H40N2O8
Solubilityinsoluble in H2O; ≥205.6 mg/mL in DMSO; ≥98.2 mg/mL in EtOH with ultrasonic
Chemical Name2,3,5-trihydroxy-7-methyl-N-[(2R)-2-phenylpropyl]-6-[1,6,7-trihydroxy-3-methyl-5-[[(2R)-2-phenylpropyl]carbamoyl]naphthalen-2-yl]naphthalene-1-carboxamide
SDFDownload SDF
Canonical SMILESCC1=C(C(=C2C=C(C(=C(C2=C1)C(=O)NCC(C)C3=CC=CC=C3)O)O)O)C4=C(C=C5C(=C4O)C=C(C(=C5C(=O)NCC(C)C6=CC=CC=C6)O)O)C
Shipping ConditionSmall Molecules with Blue Ice, Modified Nucleotides with Dry Ice.
General tips We do not recommend long-term storage for the solution, please use it up soon.

Protocol

Cell experiment:[1]

Cell lines

PC-3 human prostate cancer cells, H460 human lung cancer cells, BP3 B-cell lymphoma cells, and mouse embryonic fibroblast cells

Reaction Conditions

3 d incubation

Applications

Sabutoclax potently inhibited cell growth of human prostate cancer (3 d), lung cancer (3 d), and lymphoma (1 ~ 2 d) cell lines, with EC50 values of 0.13, 0.56, and 0.049 μM, respectively. In addition, sabutoclax (overnight incubation) showed little cytotoxicity against bax-/-bak-/- mouse embryonic fibroblast cells at 30 μM, while it killed almost 70% wild-type mouse embryonic fibroblast cells at the same concentration.

Animal experiment:[1]

Animal models

Bcl-2 transgenic mice; human prostate cancer xenografts

Dosage form

42 mg/kg for transgenic mice; 1, 3 or 5 mg/kg for the prostate cancer mouse xenograft model

Administered intraperitoneally

Applications

Sabutoclax displayed in vivo efficacy in transgenic mice models and also demonstrated superior single-agent antitumor efficacy in a prostate cancer mouse xenograft model. Therefore, sabutoclax represents a potential drug lead for the development of novel apoptosis-based therapies against cancer.

Note

The technical data provided above is for reference only.

References:

1. Wei J, Stebbins J L, Kitada S, et al. BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. Journal of medicinal chemistry, 2010, 53(10): 4166-4176.

Biological Activity

Description Sabutoclax(BI-97C1) is a inhibitor of Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 values of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.
Targets Bcl-xL Bcl-2 Mcl-1 Bfl-1    
IC50 0.31 μM 0.32 μM 0.20 μM 0.62 μM    

Quality Control